DARZALEX 20 mg/mL concentrate for solution for infusion, DARZALEX 1800 mg solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, VELCADE 3.5 mg powder for solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, Venetoclax, DEXAMETHASONE
M15-654
Phase 2 small_molecule active
Quick answer
DARZALEX 20 mg/mL concentrate for solution for infusion, DARZALEX 1800 mg solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, VELCADE 3.5 mg powder for solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, Venetoclax, DEXAMETHASONE for Multiple Myeloma is a Phase 2 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Multiple Myeloma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active